Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 2533 to 2536 of 2536 entries
Sorted by: Best Match Show Resources per page
Primary adrenal insufficiency due to bilateral adrenal infarction in COVID-19: a case report.

The Journal of clinical endocrinology and metabolism

Machado IFR, Menezes IQ, Figueiredo SR, Coelho FMA, Terrabuio DRB, Ramos DV, Fagundes GFC, Maciel AAW, Latronico AC, Fragoso MCBV, Cancado ELR, Mendonca BB, Almeida MQ.
PMID: 34324679
J Clin Endocrinol Metab. 2021 Jul 29; doi: 10.1210/clinem/dgab557. Epub 2021 Jul 29.

CONTEXT: Coronavirus disease 2019 (COVID-19) is a proinflammatory and prothrombotic condition, but its impact on adrenal function has not been adequately evaluated.CASE REPORT: A 46-year-old woman presented with abdominal pain, hypotension, skin hyperpigmentation after COVID-19 infection. The patient had...

Cite
Machado IFR, Menezes IQ, Figueiredo SR, et al. Primary adrenal insufficiency due to bilateral adrenal infarction in COVID-19: a case report. J Clin Endocrinol Metab. 2021;doi: 10.1210/clinem/dgab557.
Machado, I. F. R., Menezes, I. Q., Figueiredo, S. R., Coelho, F. M. A., Terrabuio, D. R. B., Ramos, D. V., Fagundes, G. F. C., Maciel, A. A. W., Latronico, A. C., Fragoso, M. C. B. V., Cancado, E. L. R., Mendonca, B. B., & Almeida, M. Q. (2021). Primary adrenal insufficiency due to bilateral adrenal infarction in COVID-19: a case report. The Journal of clinical endocrinology and metabolism, . https://doi.org/10.1210/clinem/dgab557
Machado, Iza F R, et al. "Primary adrenal insufficiency due to bilateral adrenal infarction in COVID-19: a case report." The Journal of clinical endocrinology and metabolism vol. (2021). doi: https://doi.org/10.1210/clinem/dgab557
Machado IFR, Menezes IQ, Figueiredo SR, Coelho FMA, Terrabuio DRB, Ramos DV, Fagundes GFC, Maciel AAW, Latronico AC, Fragoso MCBV, Cancado ELR, Mendonca BB, Almeida MQ. Primary adrenal insufficiency due to bilateral adrenal infarction in COVID-19: a case report. J Clin Endocrinol Metab. 2021 Jul 29; doi: 10.1210/clinem/dgab557. Epub 2021 Jul 29. PMID: 34324679.
Copy Download .nbib Format: NLM
Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study.

European journal of preventive cardiology

Rossi GP, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Schultze Kool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Margill SB, Shafigullina Z, Quinkler M, Oliveras A, Lee BC, Wu VC, Kratka Z, Seccia TM, Lenzini L.
PMID: 33742213
Eur J Prev Cardiol. 2021 Mar 20; doi: 10.1093/eurjpc/zwaa108. Epub 2021 Mar 20.

AIMS: We aimed at determining the rate of drug-resistant arterial hypertension in patients with an unambiguous diagnosis of primary aldosteronism (PA). Moreover, we sought for investigating the diagnostic performance of adrenal vein sampling (AVS), and the effect of adrenalectomy...

Cite
Rossi GP, Rossitto G, Amar L, et al. Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. Eur J Prev Cardiol. 2021;doi: 10.1093/eurjpc/zwaa108.
Rossi, G. P., Rossitto, G., Amar, L., Azizi, M., Riester, A., Reincke, M., Degenhart, C., Widimsky, J., Naruse, M., Deinum, J., Schultze Kool, L., Kocjan, T., Negro, A., Rossi, E., Kline, G., Tanabe, A., Satoh, F., Rump, L. C., Vonend, O., Willenberg, H. S., Fuller, P. J., Yang, J., Chee, N. Y. N., Margill, S. B., Shafigullina, Z., Quinkler, M., Oliveras, A., Lee, B. C., Wu, V. C., Kratka, Z., Seccia, T. M., & Lenzini, L. (2021). Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European journal of preventive cardiology, . https://doi.org/10.1093/eurjpc/zwaa108
Rossi, Gian Paolo, et al. "Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study." European journal of preventive cardiology vol. (2021). doi: https://doi.org/10.1093/eurjpc/zwaa108
Rossi GP, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Schultze Kool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Margill SB, Shafigullina Z, Quinkler M, Oliveras A, Lee BC, Wu VC, Kratka Z, Seccia TM, Lenzini L. Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. Eur J Prev Cardiol. 2021 Mar 20; doi: 10.1093/eurjpc/zwaa108. Epub 2021 Mar 20. PMID: 33742213.
Copy Download .nbib Format: NLM
Role of Mineralocorticoid and Angiotensin Type 1 Receptors in the Paraventricular Nucleus in Angiotensin-Induced Hypertension.

Frontiers in physiology

Burke SL, Barzel B, Jackson KL, Gueguen C, Young MJ, Head GA.
PMID: 33762970
Front Physiol. 2021 Mar 08;12:640373. doi: 10.3389/fphys.2021.640373. eCollection 2021.

The hypothalamic paraventricular nucleus (PVN) is an important site where an interaction between circulating angiotensin (Ang) and mineralocorticoid receptor (MR) activity may modify sympathetic nerve activity (SNA) to influence long-term elevation of blood pressure. We examined in conscious Ang...

Cite
Burke SL, Barzel B, Jackson KL, et al. Role of Mineralocorticoid and Angiotensin Type 1 Receptors in the Paraventricular Nucleus in Angiotensin-Induced Hypertension. Front Physiol. 2021;12:640373doi: 10.3389/fphys.2021.640373.
Burke, S. L., Barzel, B., Jackson, K. L., Gueguen, C., Young, M. J., & Head, G. A. (2021). Role of Mineralocorticoid and Angiotensin Type 1 Receptors in the Paraventricular Nucleus in Angiotensin-Induced Hypertension. Frontiers in physiology, 12640373. https://doi.org/10.3389/fphys.2021.640373
Burke, Sandra L, et al. "Role of Mineralocorticoid and Angiotensin Type 1 Receptors in the Paraventricular Nucleus in Angiotensin-Induced Hypertension." Frontiers in physiology vol. 12 (2021): 640373. doi: https://doi.org/10.3389/fphys.2021.640373
Burke SL, Barzel B, Jackson KL, Gueguen C, Young MJ, Head GA. Role of Mineralocorticoid and Angiotensin Type 1 Receptors in the Paraventricular Nucleus in Angiotensin-Induced Hypertension. Front Physiol. 2021 Mar 08;12:640373. doi: 10.3389/fphys.2021.640373. eCollection 2021. PMID: 33762970; PMCID: PMC7982587.
Copy Download .nbib Format: NLM
Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Kovarik JJ, Kaltenecker CC, Domenig O, Antlanger M, Poglitsch M, Kopecky C, Säemann MD.
PMID: 34351585
Diabetes Ther. 2021 Sep;12(9):2485-2498. doi: 10.1007/s13300-021-01118-7. Epub 2021 Aug 05.

BACKGROUND: Renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) is the cornerstone of antihypertensive treatment in patients with chronic kidney disease (CKD) and diabetes mellitus. Mineralocorticoid receptor antagonists (MRA) on top of conventional...

Cite
Kovarik JJ, Kaltenecker CC, Domenig O, et al. Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study. Diabetes Ther. 2021;12(9):2485-2498doi: 10.1007/s13300-021-01118-7.
Kovarik, J. J., Kaltenecker, C. C., Domenig, O., Antlanger, M., Poglitsch, M., Kopecky, C., & Säemann, M. D. (2021). Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study. Diabetes therapy : research, treatment and education of diabetes and related disorders, 12(9), 2485-2498. https://doi.org/10.1007/s13300-021-01118-7
Kovarik, Johannes J, et al. "Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 12,9 (2021): 2485-2498. doi: https://doi.org/10.1007/s13300-021-01118-7
Kovarik JJ, Kaltenecker CC, Domenig O, Antlanger M, Poglitsch M, Kopecky C, Säemann MD. Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study. Diabetes Ther. 2021 Sep;12(9):2485-2498. doi: 10.1007/s13300-021-01118-7. Epub 2021 Aug 05. PMID: 34351585; PMCID: PMC8384966.
Copy Download .nbib Format: NLM
Showing 2533 to 2536 of 2536 entries